Epigral Limited
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.
What Epigral files
- Investor Meet72
- Others48
- Important15
- Updates13
- Board Meeting9
- PPTs7
Epigral delivered a solid Q1 FY27. Revenue grew 15% YoY to ₹709 Cr, driven by a 5% sales volume increase and improved realization, despite macroeconomic challenges. Plant utilization remained above 80%. The company is strategically expanding its high-value specialty chemicals portfolio. New projects include an Epoxy Resin & Formulations plant...
Epigral delivered a strong Q4 FY26, reporting record revenue of ₹736 Cr, up 22% QoQ, driven by a 15% sequential volume increase. Profit After Tax (PAT) surged 109% QoQ to ₹82 Cr, with an 11% margin. For FY26, revenue was ₹2,542 Cr (down 1% YoY), and PAT stood at ₹333...
Epigral saw a 2% QoQ revenue increase to ₹603 Cr in Q3FY26, with Derivatives & Specialty contributing 52% of sales. However, EBITDA margins tightened to 17% (vs 23% in Q2FY26) due to softer realizations and higher raw material costs. For the first nine months of FY26, revenue dipped 7% to...
Epigral reported mixed financial results for Q2FY26. Revenue dipped 4% QoQ to ₹ 589 Cr, largely due to lower product realizations. EBITDA margin also compressed to 23% from 27% in Q1, impacted by these lower realizations and utilization. For H1FY26, revenue was ₹ 1,204 Cr, down 6% YoY, with EBITDA...
**Financial Highlights:** Revenue dipped 6% YoY to ₹615 Cr. EBITDA slipped 7% to ₹163 Cr, yet a strong 27% margin held. Reported PAT was ₹160 Cr (₹79 Cr sans one-time deferred tax benefit). Balance sheet looks stronger: ROCE improved to 24%, and Net Debt/EBITDA tightened to 0.6x from 1.6x YoY....